BellBrook Labs Webinar: Streamlining ATPase and Kinase Assay Development using Direct ADP Detection

Share Article

BellBrook’s Transcreener ADP Assay provides an extensively validated, generic HTS platform for ATPase and kinase assays with a choice of FP, TR-FRET or FI readouts. Dr. Robert Lowery, BellBrook’s CEO and the inventor of the Transcreener method, will describe how direct, real time ADP detection can streamline ATPase and kinase assay development, resulting in fewer pilot experiments and decreased reagent usage.

Transcreener ADP Assay: The simplest, most direct ADP detection method avaliable.

Join us for a webinar on Wednesday, May 14th at 11:00 AM CDT: Streamlining ATPase and Kinase Assay Development using Direct ADP Detection

Register now!

Biochemical HTS assays are a critical component of drug discovery programs focused on kinases and other types of ATP-dependent enzymes, such as chaperonins and helicases. Assembling, evaluating and optimizing high quality enzymes and assay reagents can be a costly and time consuming undertaking. The shift toward screening focused libraries against multiple targets in parallel can add to the assay development burden substantially.
In this webinar you will learn:

  •     How Transcreener assays work: homogenous immunodetection of nucleotides with far red fluorescent readouts.
  •     Why highly selective immunodetection of ADP is advantageous over more complex methods that rely on coupling enzymes to convert ADP to a detectable product.
  •     How monitoring ADP production in real time allows optimization of multiple assay parameters using a single reaction.
  •     How to obtain accurate IC50 values directly from raw Transcreener data, and eliminate the need for standard curves.

Participants should come away confident that they can apply a rapid, user friendly solution to screen or profile kinases and other types of ATP dependent enzymes with minimal pilot experimentation and reagent usage.

After registering, you will receive a confirmation email containing information about joining the webinar.

About BellBrook Labs. BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions for enzymes and phenotypic assays. The company’s Transcreener® HTS enzyme assays, used by all of the major pharmaceutical companies, make it easy to screen thousands of different enzymes, including validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. The iuvo™ Microconduit Array technology and assay screening service is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bob Lowery
BellBrook Labs
+1 (608) 227-4501
Email >
Visit website